Announcements Trials
Browse Landscape

Phase

Phase 4 3Phase 2 1

Status

Completed 5

Sponsor Class

INDUSTRY 5OTHER 4NIH 2

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Lymphoid 9Dermatologic 5Other hematologic neoplasm 1

Conditions

Lymphoma, T-Cell, Cutaneous 4Sezary Syndrome 2Mycosis Fungoides 2Neoplasms 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × denileukin diftitox × Dermatologic × Clear all
NCT05137847 2023-12-12

A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)

Eisai Inc.

Completed
118 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Drug-Related Side Effects and Adverse Reactions

NCT01127451 2022-04-13

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Eisai Inc.

Phase 2 Completed
75 enrolled 15 charts
Dermatologic

Melanoma, Neoplasms

NCT00050999 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients

Eisai Inc.

Phase 4 Completed
195 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00051012 2008-03-05

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

Eisai Inc.

Phase 4 Completed
86 enrolled
DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00211198 2008-03-05

Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)

Eisai Inc.

Phase 4 Completed
60 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡